Washington Center for Bleeding Disorders

What Washington Center for Bleeding Disorders does

Washington Center for Bleeding Disorders (WACBD) is a private 501(c)(3) nonprofit founded in 1974 and headquartered in Seattle, Washington. It is a federally funded Hemophilia Treatment Center and state-designated Center of Excellence that provides comprehensive care for patients with inherited and acquired bleeding disorders — primarily hemophilia A and B, von Willebrand disease, rare clotting factor deficiencies, inherited platelet disorders, and women's bleeding disorders — across Washington state through its Seattle headquarters and five outreach clinics in Spokane, Wenatchee, Tri-Cities, Olympia, and Sedro Woolley. The organization legally separated from Bloodworks Northwest in 2020 to become an independent nonprofit.

WACBD operates three integrated service lines: (1) Clinical Care Services delivering diagnosis, personalized treatment planning, specialty laboratory evaluation, physical therapy with musculoskeletal ultrasound, genetic testing and counseling, social work, and 24/7 triage; (2) a URAC- and ACHC-accredited 340B Hemophilia Pharmacy providing clotting factors, non-factor therapies, and extended half-life products with home delivery; and (3) a Clinical Research Program conducting therapeutic, translational, pathophysiologic, and observational studies including gene therapy trials, in collaboration with the University of Washington, Bloodworks Northwest, and the CDC. Underlying technology includes a NextGen patient portal, Carequality interoperability framework participation, and pediatric-to-adult care transition partnerships with Seattle Children's, Mary Bridge, and Providence Sacred Heart.

WACBD's revenue model blends insurance-based billing for clinical services, federal HTC funding, 340B pharmacy program economics (clotting factor acquisition at federal ceiling prices generating spread reinvested in patient services), and clinical research funding from federal grants and industry sponsors. The center accepts AETNA, AMERIGROUP, Blue Cross/Blue Shield, CIGNA, Kaiser, Medicare, Medicaid (Apple Health), and United Healthcare, and operates a Patient Financial Assistance Program for underinsured, uninsured, homeless, or low-income patients. Distribution is through physician-to-physician referrals, direct patient scheduling, community education (Camp I-VY for children ages 7–15), and telemedicine, with no evidence of consumer-facing marketing.

Name

Washington Center for Bleeding Disorders

Legal name

Washington Center for Bleeding Disorders

Website

https://wacbd.org

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

11–50 employees

Short description

Washington Center for Bleeding Disorders is a Seattle-based 501(c)(3) nonprofit federally funded Hemophilia Treatment Center and Center of Excellence providing comprehensive care, 340B pharmacy services, and clinical research for patients with hemophilia, von Willebrand disease, and other bleeding disorders across Washington state.

Ownership category

akta.pro rank

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. 340B Pharmacy Program: WACBD operates an in-house 340B pharmacy that generates revenue through the federal 340B Drug Pricing Program, which allows eligible healthcare organizations to obtain outpatient medications through agreements with manufacturers. Revenue is reinvested into patient services including physical therapy, education, medical care, and community programs.
2. Clinical Services Billing: The center bills insurance companies directly for comprehensive medical care including clinic visits, laboratory tests, nursing education, physical therapy, genetic counseling, and other specialized services. Accepts numerous insurance plans including Medicare, Medicaid, and commercial insurers.
3. Federal Funding: As a federally funded Hemophilia Treatment Center, WACBD receives federal support for its comprehensive care, education, and research programs serving patients with bleeding disorders across Washington state.
4. Clinical Research Funding: The center conducts clinical trials and observational studies funded through federal grants, investigator-initiated studies, and industry research collaborations with pharmaceutical companies developing new bleeding disorder treatments.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

WACBD is a federally funded Hemophilia Treatment Center providing comprehensive medical care for patients with hemophilia, von Willebrand disease, and other inherited and acquired bleeding disorders. The center integrates clinical care, an in-house 340B specialty pharmacy, physical therapy with musculoskeletal ultrasound, genetic counseling, social work, and clinical research under one organization. It serves patients across Washington state through its Seattle headquarters and five outreach clinics in Spokane, Wenatchee, Tri-Cities, Olympia, and Sedro Woolley, with home delivery pharmacy services and 24/7 emergency consultation.

Product overview

Washington Center for Bleeding Disorders (WACBD) is a federally funded Hemophilia Treatment Center and Center of Excellence offering a comprehensive suite of services for individuals with bleeding disorders. The organization operates three integrated pillars: (1) Clinical Care Services providing diagnosis, treatment, and management of hemophilia A and B, von Willebrand disease, inherited platelet disorders, fibrinogen disorders, and acquired conditions; (2) a URAC and ACHC-accredited 340B Hemophilia Pharmacy providing specialty medications including clotting factors, non-factor therapies, and extended half-life products with home delivery; and (3) a Clinical Research Program conducting therapeutic trials, pathophysiologic studies, and drug treatment trials in partnership with Bloodworks Northwest and the University of Washington. The organization also provides specialized physical therapy with musculoskeletal ultrasound, genetic testing and counseling, patient education resources, financial assistance, and outreach clinics across Washington state. WACBD participates in the Carequality health information exchange network for interoperability and maintains HIPAA compliance for protected health information.

Differentiator

Problem solved

Functional benefit

Products and services

• 340B Hemophilia Pharmacy Specialty pharmacy program providing clotting factors, non-factor therapies, and extended half-life products for hemophilia and bleeding disorders with home delivery, same-day processing for calls by noon, and round-the-clock emergency consultation. Accredited by URAC and ACHC.
• Clinical Care Services Comprehensive medical care for bleeding disorders including hemophilia A and B, von Willebrand disease, inherited platelet disorders, fibrinogen disorders, acquired conditions, and women's health/heavy menstrual bleeding. Services include diagnosis, personalized treatment plans, care coordination, specialty laboratory evaluation, nursing education, social services, genetic testing and counseling.
• Clinical Research Program Conducting clinical therapeutic, pathophysiologic, translational, and drug treatment trials, as well as observational and surveillance studies including gene therapy approaches, novel factor replacement therapies, diagnostic methods, and management strategies.
• Physical Therapy and Musculoskeletal Ultrasound Specialized physical therapy for musculoskeletal complications related to bleeding disorders including hemophilic arthropathy and hypermobility syndromes. Includes advanced musculoskeletal ultrasound imaging for joint health assessment, enabling early detection of arthropathy and monitoring of treatment outcomes.
• Genetic Testing and Counseling Genetic testing and counseling services for inherited bleeding disorders to help patients and families understand diagnosis, inheritance patterns, family planning, and treatment implications. Includes delivery planning for pregnant patients with bleeding disorders.

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, moderate and minor.

• Research Institute at Bloodworks NorthwestcoreStrategic or Co-development PartnerStrong collaborative research relationship enabling clinical and translational studies. WACBD maintains close ties with Bloodworks Northwest research programs, leveraging shared expertise in hematology and blood disorders research.
• University of WashingtoncoreStrategic or Co-development PartnerCollaborative relationship for research and academic programs. Many WACBD physicians hold faculty appointments at University of Washington School of Medicine. Joint clinical and translational research initiatives.
• Seattle Children's HospitalcoreStrategic or Co-development PartnerPediatric partner institution for seamless transitions from pediatric to adult care. Collaboration ensures continuity of care for patients diagnosed in childhood.
• Mary Bridge Children's HospitalcoreStrategic or Co-development PartnerPediatric partner institution serving eastern Washington region. Ensures pediatric-to-adult care transition support for bleeding disorder patients.
• Providence Sacred HeartcoreStrategic or Co-development PartnerPediatric partner institution in eastern Washington for comprehensive pediatric bleeding disorder care and transition to adult services.
• Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerParticipates in Community Counts, a CDC-funded public health monitoring program gathering information about health issues affecting people with bleeding disorders at U.S. Hemophilia Treatment Centers. Also collaborates with CDC's Division of Blood Disorders.
• American Thrombosis and Hemostasis Network (ATHN)coreStrategic or Co-development PartnerParticipates in ATHN Transcends, a natural history cohort study for participants with congenital or acquired blood disorders. Provides clinical researchers with uniform data collection methods.
• CarequalitymoderateTechnology or IntegrationWACBD participates in Carequality, an interoperability framework that interconnects health information networks. Improves data sharing with other healthcare providers within the network while maintaining HIPAA compliance.
• Bleeding Disorders Foundation of Washington (BDFW)coreStrategic or Co-development PartnerNonprofit foundation serving and educating the bleeding disorder community and advocating for access to care. WACBD collaborates with BDFW for patient education and community support programs.
• National Hemophilia FoundationmoderateGTM or Marketing PartnerNational nonprofit dedicated to finding better treatments and cures for inheritable bleeding disorders through education, advocacy, and research. Established 1948 with chapters throughout the country.
• World Federation of HemophiliamoderateGTM or Marketing PartnerInternational organization committed to treatment for all for people with bleeding disorders, regardless of where they live. Believes access to care should not be determined by geography.
• Alaska Bleeding Disorder CenterminorStrategic or Co-development PartnerWACBD hematologist Dr. Jason Taylor has worked with Alaska center since 2012, providing telemedicine and periodic in-person visits in Anchorage.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• CVS Specialty: Large national specialty pharmacy dispensing hemophilia therapies and other high-cost biologics. Competes with WACBD's 340B pharmacy for payer-driven prescriptions but does not deliver the integrated clinical/research model.
• Accredo (Evernorth Specialty Pharmacy): National specialty pharmacy dispensing high-cost clotting factor and non-factor hemophilia therapies. Overlaps directly with WACBD's 340B pharmacy offering but competes on payer contracts rather than clinical care integration.

Direct peers

• Hemophilia Treatment Center at UCSF Benioff Children's Hospital: University-affiliated HTC on the West Coast providing integrated pediatric-to-adult bleeding disorder care and research. Comparable care model including pediatric-to-adult transition pathways similar to WACBD's Seattle Children's partnership.
• Bloodworks Northwest: Regional blood center and former parent organization of WACBD. Operates overlapping hematology research programs and continues to collaborate with WACBD on translational bleeding disorder research, sharing patient population and clinical expertise.
• OHSU Hemophilia Treatment Center: Oregon Health & Science University's federally funded HTC serving the Pacific Northwest. Closest geographic peer to WACBD and provides similar comprehensive care, research, and 340B-supported pharmacy services.
• Hemophilia Center of Western Pennsylvania: Multi-disciplinary HTC delivering clinical care, specialty pharmacy, and research for bleeding disorders in western Pennsylvania. Directly comparable as a regional HTC with integrated clinical and research programs.
• Indiana Hemophilia & Thrombosis Center: One of the largest federally funded Hemophilia Treatment Centers in the U.S., offering integrated clinical care, specialty pharmacy, and research for bleeding and clotting disorders. Highly comparable to WACBD as a multi-site HTC with research and pharmacy operations.
• Mountain States Hemophilia & Thrombosis Center: Federally funded HTC in Colorado providing comprehensive bleeding disorder care, clinical research, and patient education. Comparable in scope (clinical care + research + outreach) and patient population to WACBD.

Others

• National Bleeding Disorders Foundation (formerly NHF): National nonprofit advocacy and education organization for the bleeding disorders community. WACBD partners with NBDF for patient education and community programs; comparable as a mission-aligned ecosystem participant.
• American Thrombosis and Hemostasis Network (ATHN): National nonprofit that operates the ATHN Transcends cohort study in which WACBD participates. Functions as a research/data backbone and ecosystem participant rather than a clinical competitor.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wacbd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Washington Center for Bleeding Disorders